Stephen D. Wiviott, MD: Results and Implications of the DECLARE-TIMI 58 Trial

Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on Cardiovascular Events (DECLARE TIMI-58) trial, which he presented at the American Heart Association 2018 Scientific Sessions in Chicago.

DECLARE-TIMI 58 tested the hypotheses that dapagliflozin is safe and efficacious for the reduction in the occurrence of important cardiovascular events. DECLARE-TIMI 58 is the largest trial with an SGLT-2 inhibitor to address these questions in a broad population of patients with Type 2 diabetes mellitus, and includes participants both with established cardiovascular disease and those without cardiovascular disease, but with multiple cardiovascular risk factors.

Read the full DocWire News report on DECLARE-TIMI 58 here.

Read more coverage of the AHA 2018 Scientific Sessions here.

Eric Raible is editor of the Cardiology section of DocWire News and has more than a decade’s worth of experience in covering and publishing in the cardiology space. Eric has previously served as a founding editor of CardioSource WorldNews, and is a former staff writer and editor of Cardiology Today.